SCHEMBL420818

SCHEMBL420818

CCCCCCCCCCC(CCCCCCCC)COC(=O)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 2/20 0.68
PRSS2 P07478 1/20 0.68
PRSS3 P35030 1/20 0.68
ALDH1A1 P00352 8/20 0.58
CYP3A4 P08684 2/20 0.58
CA2 P00918 1/20 0.58
LMNA P02545 6/20 0.56
HSD17B10 Q99714 1/20 0.56
MAPK1 P28482 2/20 0.52
TSHR P16473 2/20 0.52
TDP1 Q9NUW8 1/20 0.49
ADRB2 P07550 2/20 0.48
ADRB1 P08588 2/20 0.48
ADRB3 P13945 2/20 0.48
NPC1 O15118 1/20 0.47
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
CTSG P08311 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6264048 1.00 PRSS1 (0.68) PRSS1PRSS2PRSS3ALDH1A1CYP3A4
SCHEMBL3745080 0.98 PRSS1 (0.66) PRSS1PRSS2PRSS3ALDH1A1CYP3A4
Benzoic Acid SCHEMBL8017354 0.96 PRSS1 (0.63) PRSS1PRSS2PRSS3ALDH1A1CYP3A4
SCHEMBL633459 0.95 PRSS1 (0.62) PRSS1PRSS2PRSS3ALDH1A1CYP3A4
SCHEMBL571011 0.95 PRSS1 (0.65) PRSS1PRSS2PRSS3ALDH1A1CYP3A4
SCHEMBL3320267 0.94 PRSS1 (0.77) PRSS1PRSS2PRSS3ALDH1A1CYP3A4
SCHEMBL27678787 0.93 PRSS1 (0.59) PRSS1PRSS2PRSS3ALDH1A1CYP3A4
SCHEMBL30437742 0.93 PRSS1 (0.74) PRSS1PRSS2PRSS3ALDH1A1CYP3A4
SCHEMBL2822334 0.92 PRSS1 (0.64) PRSS1PRSS2PRSS3ALDH1A1CYP3A4
Benzoic Acid SCHEMBL28210602 0.92 PRSS1 (0.58) PRSS1PRSS2PRSS3ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 513 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115175665-B Drug containing Sofospiramide 科研制药株式会社 2024-04-16 CN claimed
US-20240041748-A1 INVERSE EMULSION COMPRISING AT LEAST ONE FATTY ALCOHOL, A NON-IONIC SUGAR ESTER, ETHYLCELLULOSE AND METHOD EMPLOYING IT L'OREAL (FR) 2024-02-08 US claimed
CN-117042748-A Inverse emulsion comprising at least one fatty alcohol, a nonionic sugar ester, ethylcellulose, and a method employing the inverse emulsion 莱雅公司 2023-11-10 CN claimed
EP-4262684-A1 INVERSE EMULSION COMPRISING AT LEAST ONE FATTY ALCOHOL, A NON-IONIC SUGAR ESTER, ETHYLCELLULOSE AND METHOD EMPLOYING IT L'OREAL (FR) 2023-10-25 EP claimed
US-20230241044-A1 TREATMENT FOR PSORIASIS AND SKIN INFLAMMATORY DISEASES ZYDUS LIFESCIENCES LIMITED (IN) 2023-08-03 US claimed
US-20230149349-A1 MEDICAMENT CONTAINING SOFPIRONIUM BROMIDE KAKEN PHARMACEUTICAL CO., LTD. (JP) 2023-05-18 US claimed
EP-4157233-A1 TREATMENT FOR PSORIASIS AND SKIN INFLAMMATORY DISEASES Zydus Lifesciences Limited (IN) 2023-04-05 EP claimed
CN-115666539-A Treatment of psoriasis and skin inflammatory diseases 兹杜斯生命科学有限公司 2023-01-31 CN claimed
WO-2022238745-A1 TOPICAL PHARMACEUTICAL COMPOSITION OF HIF PROLYL HYDROXYLASE INHIBITORS ZYDUS LIFESCIENCES LIMITED (IN) 2022-11-17 WO claimed
CN-115175665-A Medicine containing suopyram bromide 科研制药株式会社 2022-10-11 CN claimed
WO-2009035484-A1 LIP GLOSS NGUYEN LETHU T (US) 2009-03-19 WO claimed
US-20090060857-A1 LIP GLOSS COTY S.A.S. (FR) 2009-03-05 US claimed
US-20090047229-A1 LIP GLOSS COTY S.A.S (FR) 2009-02-19 US claimed
WO-2008156723-A2 LIP GLOSS COTY S.A.S (FR) 2008-12-24 WO claimed
US-20080267896-A1 Continuous liquid fatty phase; non-silicone oils; for application to skin, hair L'OREAL S.A. (FR) 2008-10-30 US claimed
US-6579907-B1 Gelling agent is crosslinked acrylic polymer L'OREAL S.A. (FR) 2003-06-17 US claimed
US-6344205-B1 ISONONYL, ISONONANOATE, SILICONE OIL, PULVERULENT COMPOUND L'OREAL S.A. (FR) 2002-02-05 US claimed
US-20020012643-A1 MAKE-UP REMOVING COMPOSITION L'OREAL, S.A. (FR) 2002-01-31 US claimed
US-6162834-A Foaming oil-in-water emulsion based on nonionic surfactants, a fatty phase and a crosslinked cationic or anionic polymer, and its use in topical applications L'OREAL (FR) 2000-12-19 US claimed
EP-0739619-B1 Foaming o/w emulsion based on non-ionic surfactants, a fatty phase and a cross-linked cationic or anionic polymer for topical use OREAL (FR) 1998-01-14 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149349-A1 MEDICAMENT CONTAINING SOFPIRONIUM BROMIDE SIGMAR1, PEF1, OPRK1 PRSS1 692/4885PRSS2 772/4885PRSS3 270/4885
US-20080267896-A1 Continuous liquid fatty phase; non-silicone oils; for application to skin, hair KRT18, CUTA, DEGS1 PRSS1 3319/4885PRSS2 2727/4885PRSS3 2780/4885
US-20230241044-A1 TREATMENT FOR PSORIASIS AND SKIN INFLAMMATORY DISEASES P4HA1, PAH, TNF PRSS1 670/4885PRSS2 2541/4885PRSS3 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.